Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, MarketBeat reports. Stifel Nicolaus currently has $26.00 target price on the medical device company’s stock, up from their previous target price of $22.00.

A number of other equities research analysts have also recently issued reports on TNDM. Royal Bank Of Canada reissued an “outperform” rating and set a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a report on Friday, August 7th. Mizuho set a $20.00 target price on Tandem Diabetes Care in a research report on Friday, November 6th. Canaccord Genuity Group set a $40.00 price target on Tandem Diabetes Care in a report on Friday, August 7th. Citigroup reduced their price target on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. Finally, Truist Financial reduced their price target on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.39.

View Our Latest Report on TNDM

Tandem Diabetes Care Trading Up 3.9%

NASDAQ TNDM opened at $17.46 on Wednesday. The company’s 50 day moving average is $17.25 and its 200-day moving average is $18.78. Tandem Diabetes Care has a 12-month low of $12.26 and a 12-month high of $29.65. The company has a debt-to-equity ratio of 4.47, a current ratio of 3.20 and a quick ratio of 2.65.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.15. The company had revenue of $283.69 million for the quarter, compared to analysts’ expectations of $265.85 million. Tandem Diabetes Care had a negative net margin of 4.58% and a negative return on equity of 35.61%. Tandem Diabetes Care’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.31) EPS. Equities research analysts predict that Tandem Diabetes Care will post -0.61 earnings per share for the current year.

Insider Activity

In other news, Director Christopher J. Twomey sold 1,700 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares in the company, valued at approximately $467,911.10. This trade represents a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.10% of the company’s stock.

Institutional Trading of Tandem Diabetes Care

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC boosted its stake in Tandem Diabetes Care by 157.4% during the second quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company’s stock valued at $51,058,000 after buying an additional 2,068,838 shares during the period. GW&K Investment Management LLC grew its position in Tandem Diabetes Care by 13.0% during the third quarter. GW&K Investment Management LLC now owns 2,903,529 shares of the medical device company’s stock worth $47,357,000 after buying an additional 334,497 shares in the last quarter. Defilade Capital Management L.P. bought a new position in Tandem Diabetes Care in the 1st quarter worth about $14,606,000. Quantinno Capital Management LP increased its stake in Tandem Diabetes Care by 123.5% in the 1st quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company’s stock worth $12,535,000 after acquiring an additional 361,361 shares during the last quarter. Finally, Toronto Dominion Bank bought a new position in Tandem Diabetes Care in the 3rd quarter worth about $8,308,000.

Tandem Diabetes Care Company Profile

(Get Free Report)

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

Further Reading

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.